BRPI0816784A8 - Fatores neuro-endócrinos para o tratamento de doenças degenerativas - Google Patents

Fatores neuro-endócrinos para o tratamento de doenças degenerativas

Info

Publication number
BRPI0816784A8
BRPI0816784A8 BRPI0816784A BRPI0816784A BRPI0816784A8 BR PI0816784 A8 BRPI0816784 A8 BR PI0816784A8 BR PI0816784 A BRPI0816784 A BR PI0816784A BR PI0816784 A BRPI0816784 A BR PI0816784A BR PI0816784 A8 BRPI0816784 A8 BR PI0816784A8
Authority
BR
Brazil
Prior art keywords
treatment
neuro
polypeptide
degenerative diseases
endocrine factors
Prior art date
Application number
BRPI0816784A
Other languages
English (en)
Portuguese (pt)
Inventor
Bosserhoff Anja
Schubert Thomas
Hustert Elisabeth
Original Assignee
Scil Tech Gmbh
Formycon Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07018131A external-priority patent/EP2036921A1/en
Application filed by Scil Tech Gmbh, Formycon Gmbh filed Critical Scil Tech Gmbh
Publication of BRPI0816784A2 publication Critical patent/BRPI0816784A2/pt
Publication of BRPI0816784A8 publication Critical patent/BRPI0816784A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
BRPI0816784A 2007-09-14 2008-09-12 Fatores neuro-endócrinos para o tratamento de doenças degenerativas BRPI0816784A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07018131A EP2036921A1 (en) 2007-09-14 2007-09-14 Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
EP08006810 2008-04-03
PCT/EP2008/007579 WO2009033715A2 (en) 2007-09-14 2008-09-12 Neuroendocrine factors for treatment of degenerative diseases

Publications (2)

Publication Number Publication Date
BRPI0816784A2 BRPI0816784A2 (pt) 2015-03-24
BRPI0816784A8 true BRPI0816784A8 (pt) 2016-01-19

Family

ID=40452588

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816784A BRPI0816784A8 (pt) 2007-09-14 2008-09-12 Fatores neuro-endócrinos para o tratamento de doenças degenerativas

Country Status (13)

Country Link
US (1) US20110002972A1 (show.php)
EP (1) EP2212344B1 (show.php)
JP (1) JP2010539123A (show.php)
KR (1) KR20100075493A (show.php)
CN (1) CN101821283A (show.php)
AU (1) AU2008297889A1 (show.php)
BR (1) BRPI0816784A8 (show.php)
CA (1) CA2699411A1 (show.php)
MX (1) MX2010002716A (show.php)
NZ (1) NZ583851A (show.php)
RU (1) RU2496790C2 (show.php)
WO (1) WO2009033715A2 (show.php)
ZA (1) ZA201001644B (show.php)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1400024B1 (it) * 2010-05-21 2013-05-17 Uni Politecnica Delle Marche Uso farmaceutico di semaforine.
CN103703021A (zh) * 2010-12-23 2014-04-02 赛诺菲 用于治疗肝癌的Robo1-Fc融合蛋白
EP3653218B1 (en) * 2011-07-04 2024-12-18 Mesoblast, Inc. Treating or preventing rheumatic disease
CN104582727B (zh) * 2012-06-15 2018-04-27 财团法人峩山社会福祉财团 利用Slit-Robo系统用于预防或治疗骨折或骨质疏松症的组合物
ES2442242B1 (es) * 2012-08-09 2014-11-25 Biotechnology Institute, I Mas D, S.L. Composición con factores de crecimiento destinada al tratamiento intranasal de una enfermedad neurodegenerativa u otra patología del sistema nervioso central, y su método de fabricación.
CN104119448A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119445A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119447A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
CN104119446A (zh) * 2013-04-26 2014-10-29 李华顺 含有富含亮氨酸重复序列的融合蛋白及其制法和应用
JPWO2015072527A1 (ja) * 2013-11-13 2017-03-16 国立大学法人大阪大学 ネトリン１含有破骨細胞形成抑制剤
PT3116521T (pt) 2014-03-14 2024-10-15 Univ New York State Res Found Regulação neurogénica de crescimento ósseo e degradação óssea
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US20200397860A1 (en) * 2018-02-14 2020-12-24 Cornell University Slit and bone growth modulation
KR102353524B1 (ko) * 2019-02-27 2022-01-20 주식회사 대웅제약 알부민이 결합된, Slit3 단백질의 LRRD2를 포함하는 골 관련 질환 예방 또는 치료용 조성물
EP4028532A1 (en) * 2019-09-13 2022-07-20 Rutgers, the State University of New Jersey Aav-compatible laminin-linker polymerization proteins
CN110711244B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎搽剂中的应用
CN110684805B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 神经导向因子Sema基因重组慢病毒载体在制备治疗骨关节炎药物中的应用
CN110841057B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎巴布膏剂中的应用
CN110721308B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种用于治疗骨关节炎的药物复方制剂及其制备方法
CN110772632B (zh) * 2019-11-19 2023-08-11 四川大学华西医院 神经导向因子semaphorin 3a在制备治疗骨关节炎药物中的用途
CN110694051B (zh) * 2019-11-19 2023-08-01 四川大学华西医院 一种神经导向因子Sema在制备治疗骨关节炎注射剂中的应用
EP4378480A1 (en) * 2021-07-26 2024-06-05 Purotech Bio, Inc. Anti-hepatitis b virus agent targeting host factor lipg

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2700117B1 (fr) * 1993-01-07 1995-02-03 Rhone Poulenc Rorer Sa Application d'anticonvulsivants dans le traitement de la maladie de Parkinson et des syndromes parkinsoniens.
JPH1116490A (ja) * 1997-06-26 1999-01-22 Kyocera Corp プラズマディスプレイパネル用隔壁の製造方法及びプラズマディスプレイパネル用基板
US20030032057A1 (en) * 1997-08-26 2003-02-13 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO1999023219A1 (en) * 1997-10-31 1999-05-14 Osiris Therapeutics, Inc. Human slit polypeptide and polynucleotides encoding same
JPH11164690A (ja) * 1997-12-05 1999-06-22 Asahi Chem Ind Co Ltd 脊椎動物スリット蛋白質
US20030096955A1 (en) * 1998-09-01 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2365214A1 (en) * 1999-03-17 2000-09-21 Washington University Vertebrate protein slit, dna sequence encoding it and uses thereof
WO2002006315A2 (en) * 2000-07-18 2002-01-24 Compugen Ltd. Novel nucleic acid and amino acid sequences
CA2416732C (en) * 2000-08-02 2016-02-09 Brad St. Croix Endothelial cell expression patterns
JP2004523210A (ja) * 2000-08-10 2004-08-05 ファルマシア・コーポレーション ＨＳ−５ストロマ細胞系統由来のｃＤＮＡライブラリーから得られた新規Ｓｌｉｔ‐様蛋白質
WO2002081745A2 (en) * 2001-04-05 2002-10-17 Proskelia Pharmaceuticals Genes involved in osteogenesis, and methods of use
US20050014680A1 (en) * 2003-04-15 2005-01-20 Crabtree Gerald R. Methods and compositions for enhancing neuron growth and survival
WO2005074556A2 (en) * 2004-01-30 2005-08-18 The General Hospital Corporation Netrin compositions and methods of use thereof
EP2104509A4 (en) * 2006-12-11 2010-03-24 Univ Utah Res Found COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL ANGIOGENESIS AND VASPERMEABILITY

Also Published As

Publication number Publication date
RU2010114713A (ru) 2011-10-20
ZA201001644B (en) 2011-03-30
CN101821283A (zh) 2010-09-01
EP2212344B1 (en) 2014-03-26
KR20100075493A (ko) 2010-07-02
JP2010539123A (ja) 2010-12-16
WO2009033715A3 (en) 2010-03-18
AU2008297889A1 (en) 2009-03-19
MX2010002716A (es) 2010-07-05
RU2496790C2 (ru) 2013-10-27
NZ583851A (en) 2012-06-29
US20110002972A1 (en) 2011-01-06
EP2212344A2 (en) 2010-08-04
WO2009033715A2 (en) 2009-03-19
CA2699411A1 (en) 2009-03-19
BRPI0816784A2 (pt) 2015-03-24

Similar Documents

Publication Publication Date Title
BRPI0816784A8 (pt) Fatores neuro-endócrinos para o tratamento de doenças degenerativas
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
CO6640289A2 (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
BR112012022214A2 (pt) métodos e composições para tratar doença de degos
MX349513B (es) Materiales y metodos para el tratamiento o prevencion de enfermedades asociadas al her-3.
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
BRPI0922350A2 (pt) anticorpo humano, mólecula biespecífica,vetor de expressão, célula hospedeira eucariótica ou procariótoca recombinante, composição farmacêutica, uso do anticorpo ou da molécula biespecífica, métodos para inibir o desenvolvimento e/ou proliferação de uma célula tumoral que expressa o fator de tecido, para produzir um anticorpo, e para detectar a presença de fator de tecido em uma amostra, composição de diagnóstico, e, kit para detectar a presença de fator de tecido em uma amostra.
BRPI0921999B8 (pt) uso de uma quantidade terapeuticamente eficaz de células tronco placentárias
AR080891A1 (es) Proteina de fusion robo 1-fc y su utilizacion en el tratamiento de tumores
AR074360A1 (es) Anticuerpo monoclonal o fragmento de union a antigeno del mismo composicion farmaceutica que lo comprende y su uso para preparar dicha composicion
CR20110470A (es) Proteínas de union a il-17
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
NO20083793L (no) Antistoffer mot amyloid-beta peptid
CL2007002350A1 (es) Compuestos derivados de isoxazolinas; composicion que comprende al menos uno de dichos compuestos; procedimiento para controlar insectos daninos; uso del compuesto o de la composicion; procedimientos para preparar dichos compuestos; y compuestos inte
BRPI0906478B8 (pt) anticorpo anti-nr10, seu uso e composição farmacêutica que o compreende
BR112018011002A2 (pt) variantes de fgf21
IL194550A (en) Isolated antibodies or their fragments that bind to human protein tyrosine phosphate in a cell, their pharmaceutical preparations and their use
SV2010003581A (es) 4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
EA201000559A1 (ru) Композиции и способы применения антител к склеростину
ECSP14001249A (es) Inmunoenlazadores dirigidos contra el tnf
AR113422A2 (es) Agentes tensioactivos reconstituidos que tienen propiedades mejoradas
BRPI0911203A2 (pt) peptídeo ou derivado de peptídeo, composição farmacêutica, uso de um peptídeo ou derivado de peptídeo, métodos para tratar um paciente tendo uma deficiencia e para preparar o peptídeo ou derivado de peptídeo.
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CL2009000862A1 (es) Anticuerpo aislado, derivados o fragmentos aislados del mismo capaz de unirse a la proteina cd151, composición que lo comprende; ácido nucleico que lo codifica, vector y célula huesped que lo comprenden; procedimiento para preparar dicho anticuerpo; util como medicamento para prevenir o tratar el cáncer.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B25A Requested transfer of rights approved

Owner name: FORMYCON GMBH (DE)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.